Introduction: Alzheimer's disease (AD) is a world-wide health problem with implications for
an increasing number of people and countries. Populations suffering from AD financially …

Alzheimer's disease (AD), once considered a rare disease, is now the most common form of
dementia in the elderly population. Current drugs (cholinesterase inhibitors and glutamate …

Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition
with rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) …

Objective: To examine the role of butyrylcholinesterase (BuChE) in cholinergic signaling and
neurologic conditions, such as Alzheimer's disease (AD). The rationale for inhibiting …

Background/Objectives To examine the comparative effectiveness and safety of cognitive
enhancers for Alzheimer's disease (AD). Design Systematic review and Bayesian network …

Alzheimer disease (AD) and Parkinson disease (PD) are the most common
neurodegenerative disorders. For both diseases, early intervention is thought to be essential …

Decades of research have produced no effective method to prevent, delay the onset, or slow
the progression of Alzheimer's disease (AD). In contrast to these failures …

Introduction: Both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are
present in the body in large amounts. AChE is an important part of the cholinergic nervous …

Acetylcholinesterase (AChE) is a cholinergic enzyme primarily found at postsynaptic
neuromuscular junctions, especially in muscles and nerves. It immediately breaks down or …

Alzheimer disease is a multifactorial pathology and the development of new multitarget
neuroprotective drugs is promising and attractive. We synthesized a group of original …